This new blood test could detect cancer before it shows up on scans
Why it matters: This breakthrough could revolutionize cancer diagnostics, shifting from reactive treatment to proactive prevention and personalized care, ultimately saving lives and reducing healthcare costs.
- Shenzhen University Researchers have created a light-based sensor that uses DNA nanotechnology, CRISPR, and quantum dots to detect cancer biomarkers at sub-attomolar levels, even in real patient serum samples.
- The new technology eliminates the need for chemical amplification, a common step in current biomarker tests, making the process faster, simpler, and cheaper.
- Early diagnosis of lung cancer is now closer to reality, with the potential for simple blood screenings before tumors are visible on CT scans, as well as personalized treatment monitoring through frequent biomarker level assessments.
A groundbreaking CRISPR-powered light sensor, developed by researchers at Shenzhen University, can detect minuscule amounts of cancer biomarkers in blood with unprecedented sensitivity, potentially enabling earlier cancer detection than current imaging techniques. This innovation promises simpler, more frequent monitoring of disease progression and treatment efficacy, offering a path to personalized medicine and improved survival rates.
